News | April 03, 2025
Asahi Kasei Life Science begins operation
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Overall investment in the US facility is estimated around US$50 million
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Investment will fund expansion to meet rising demand for CRDMO services
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Q2 FY25 Total Income was at Rs. 85.4 crore
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
Subscribe To Our Newsletter & Stay Updated
